Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 25 2021 - 5:07AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
May
2021
Commission
File Number: 0001723069
Tiziana
Life Sciences plc
(Exact
Name of Registrant as Specified in Its Charter)
3rd Floor,
11-12
St James’s Square
London
SW1Y 4LB
United
Kingdom
(Address
of registrant’s principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K
On
May 25, 2021, Tiziana Life Sciences plc (the “Company”) issued a regulatory news service announcement in the United
Kingdom announcing the Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration
of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program (the “RNS Announcement”).
The
RNS Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibit 99.1
is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of
1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by
the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein
or as shall be expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
TIZIANA LIFE SCIENCES PLC
|
|
|
|
|
Date: May 25, 2021
|
By:
|
/s/
Kunwar Shailubhai
|
|
|
Name:
|
Kunwar Shailubhai
|
|
|
Title:
|
Chief Executive Officer
|
EXHIBIT INDEX
3
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Jul 2023 to Jul 2024